Boehringer Ingelheim Fremont, Inc.
6701 Kaiser Drive
About Boehringer Ingelheim Fremont, Inc.
Boehringer Ingelheim Fremont, Inc. is part of Boehringer Ingelheim Biopharmaceuticals GmbH, a leading biopharmaceutical contract manufacturer, known under the brand name Boehringer Ingelheim BioXcellence™. As a mammalian cell culture center in the heart of Silicon Valley, more than 600 scientists and specialists are committed to research, development and manufacturing to make high quality medicines for patients. Our modern facility offers high flexibility with stainless steel and single-use bioreactors for fed-batch and continuous manufacturing. With the complete range of services, from cell line and strain development including high expression systems through process development and large-scale manufacturing, to Fill & Finish we help our customers to turn innovative biologic ideas into commercial reality. Boehringer Ingelheim Biopharmaceuticals GmbH has over 35 years of biotechnology experience, more than 4,600 dedicated and highly trained employees. With our global network, we have helped customers to bring more than 35 molecules to the market. Our network of facilities spans the globe, from Fremont, California in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China for manufacturing in mammalian cell culture and microorganisms. We are one integrated global team with one shared passion: Your product.
Biopharmaceuticals - Competence and Experience for Medicines of the Future Over 35 years ago, Boehringer Ingelheim started developing and producing biopharmaceuticals as one of the first companies worldwide. Biopharmaceuticals are produced by using either mammalian cell cultures or microorganisms such as bacteria or yeast.
950 articles with Boehringer Ingelheim Fremont, Inc.
Platelet Biogenesis (PBG) was awarded a two-year, $3.5 million grant from the U.S. Department of Defense (DoD). The funds are to support the company’s proprietary bioreactor to produce therapeutic amounts of platelets.
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in A1C after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10 and 25 mg).
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
New Biologicals Development Center in Biberach, Germany bundles biologics development, increases capacity and expands clinical supply network
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Boehringer Ingelheim announced that Praxbind® (idarucizumab) is now stocked in 3,200 hospitals in all 50 states.
Bactevo Ltd. announced that it has entered into a drug discovery collaboration agreement with Boehringer Ingelheim to identify novel small molecule lead compounds.
4/27/2018Humira, the world’s best-selling drug, keeps on churning out positive sales results for AbbVie, despite looming challenges.
Boehringer Ingelheim and HealthPrize Technologies today announced the expansion of the RespiPoints digital support program to anyone taking one of several Boehringer Ingelheim medicines, including select medicines available in the Respimat inhaler.
Decision converts Praxbind's accelerated approval, granted in October 2015, to full approval.
Sanofi has agreed to sell its generics division, Zentiva, to Advent International. The deal is expected to wrap by the end of this year.
The last week has marked plenty of investment activity in operations, collaborations and PR the last week or two for Ingelheim, Germany-based Boehringer Ingelheim.
Boehringer Ingelheim and OSE Immunotherapeutics signed a collaboration and license deal to jointly develop OSE-172 for myeloid cancers.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
$54 Million Aggrenox® Class Action Settlement is Reached by Miller Law LLC, Hilliard & Shadowen LLP, and Heins Mills & Olson, P.L.C.
A proposed $54 million settlement has been reached in a class action lawsuit regarding the prescription drug Aggrenox® (aspirin/extended-release dipyridamole).
Three Leading Animal Health Companies Join Hands to Launch World-Class Vaccine Joint Venture Targeting Foot-and-Mouth Disease in China
Boehringer Ingelheim, KMOH, and ZNWT establish a vaccine joint venture targeting foot-and-mouth disease control and prevention in China; The vaccine manufacturing project is located at the Airport New City in Xi’an with a total investment of 840 million yuan (around €108 million); The venture will introduce the world’s leading vaccine technology and expertise against foot-and-mouth disease in a bid to shape the future market in China
FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill an unmet medical need.
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
-- Boehringer Ingelheim and Vanderbilt University collaborate to develop novel anti-cancer drugs that inhibit the MCL1 (myeloid cell leukemia 1) protein -- There are no existing therapies targeting MCL1, which is highly prevalent in many difficult-to-treat cancers -- This is the third collaboration between Boehringer Ingelheim and Vanderbilt University
Giuseppe Ciaramella, formerly chief scientific officer of Moderna Therapeutics’ Valera unit, has left for an unidentified stealth-mode biotech startup.
Boehringer Ingelheim Demonstrates Their Commitment to Site Relationships by Joining SCRS’ Global Impact Partner Program
Becoming a GIP demonstrates the company’s commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions.